Comparative Pharmacology
Head-to-head clinical analysis: DERMATOP versus LOCAMETZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMATOP versus LOCAMETZ.
DERMATOP vs LOCAMETZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prednicarbate is a corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of arachidonic acid from membrane phospholipids.
Metformin hydrochloride is a biguanide antihyperglycemic agent that improves glucose tolerance in patients with type 2 diabetes mellitus. It primarily decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Apply a thin layer to affected skin areas twice daily (morning and evening) for up to 4 weeks. Do not use more than 50 g per week.
Locametz (gallium Ga 68 gozetotide) is administered intravenously at a dose of 3-5 mCi (110-185 MBq) as a single injection for PET imaging. No repeated dosing schedule is defined.
None Documented
None Documented
Terminal elimination half-life: approximately 100 hours (range 68-120 hours) following topical administration; prolonged accumulation with chronic use due to high lipophilicity and slow release from skin depot.
Terminal elimination half-life of 14 hours (range 12-16 h); clinically, steady-state achieved after 3 days.
Primarily hepatic metabolism with inactive metabolites; <10% excreted renally as unchanged drug; minimal biliary/fecal elimination.
Primarily renal excretion (70% unchanged), with 20% fecal elimination via biliary secretion; 10% metabolized.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid